European Companies Search Engine

EU funding (€10.9M): ERA-NET: Sustained collaboration of national and regional programmes in cancer research Hor 5 Feb 2021 EU Research and Innovation programme "Horizon"

Overview

Text

ERA-NET: Sustained collaboration of national and regional programmes in cancer research

Cancer is a worldwide health burden and a major public health challenge. Despite significant advances in the understanding, prevention, diagnostics and treatment, cancer remains a public health problem in Europe and the world. In such a setting, translational cancer research plays a key role in successfully addressing the growing burden of cancer. The great potential of translational cancer research in Europe will only be achieved when the main barriers are systematically addressed through concerted actions between public and private organisations that provide funds for research, researchers, healthcare providers and all those engaged in the cancer research spectrum. Moreover, adequate and systematic financial support backed by a strong political commitment is absolutely essential to help reduce the burden of cancer that European citizens are currently facing. In this context, the TRANSCAN-3 network, with a strong background in funding cancer research, embodies an excellent model of cross-national cooperation by bringing together 31 funding organisations, from 20 countries, with the common goal of supporting high-impact translational cancer research through cross-national joint calls for proposals, and by an efficient investment of dedicated national/regional public funding, leveraged with foundation/charity-based resources and EU financial support. Building up on the well-established cooperation and accomplishments, through the harmonisation of national/regional funding mechanisms and programmes, plus continued and sustained series of efforts for the access to and sharing of data on cancer research, this TRANSCAN-3 project also aims at becoming a catalysts for a sustainable model of funding of high-impact cancer research in Europe and beyond, with an approach to effectively engage relevant stakeholders (patients, society as a whole, policy makers, etc.) in different stages of the action.


Funded Companies:

Company name Funding amount
Aicib - Agencia de Investigacao Clinica e Inovacao Biomedica €11,962.50
Alleanza Contro IL Cancro €207,574
Bundesministerium Fuer Forschung Technologie UND Raumfahrt €1,537,424
Canadian Institutes OF Health Research €0.00
Deutsches Zentrum FUR Luft - UND Raumfahrt e. V. €59,813
Fondation ARC Pour la Recherche sur le Cancer €404,589
Fondazione Regionale Per LA Ricerca Biomedica €552,350
Fonds de la Recherche Scientifique- FNRS €158,320
Fonds Voor Wetenschappelijk Onderzoek-Vlaanderen €404,589
Fonds ZUR Förderung DER Wissenschaftlichen Forschung €453,842
Fundacao para A Ciencia e A Tecnologia €109,066
Fundacion Cientifica de La Asociación Espanola Contra El Cancer €256,827
Fundacion para El Fomento en Asturias de La Investigacion Cientifica y La Tecnologia €158,320
Geniki Grammatia Erevnas Kai Kainotomias €47,850
Institut National du Cancer GIP €798,618
Instituto de Salud Carlos III €306,081
Istituto Superiore Di Sanita €59,813
Kreftforeningen €306,081
Latvijas Zinatnes Padome €256,827
Ministero Dell'Universita E Della Ricerca €355,335
Ministero Della Salute €1,783,693
Ministry OF Health €207,574
Narodowe Centrum Badan i Rozwoju €650,857
National Science AND Technology Council €0.00
Nemzeti Kutatasi Fejlesztesi ES Innovacios Hivatal €207,574
Norges Forskningsrad €306,081
Regione Toscana €207,574
Sihtasutus Eesti Teadusagentuur €109,066
Slovenska Akademia Vied €178,021
The Health Research Board €242,051
Turkiye Bilimsel VE Teknolojik Arastirma Kurumu €306,081
Unitatea Executiva Pentru Finantarea Invatamantului Superior a Cercetarii Dezvoltarii si Inovarii €306,081
Valsts Izglitibas Attistibas Agentura €0.00

Source: https://cordis.europa.eu/project/id/964264

The filing refers to a past date, and does not necessarily reflect the current state.